Associate Professor, Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center, Southwestern Medical School
Neurology
Dr. Olaf Stuve, MD
|
|
Give Review
Olaf Stuve practices Neurology. Olaf Stuve, MD is a published doctor. He has 52 papers published. The most current publication "Interferon beta in the treatment of multiple sclerosis: mechanisms of action."
Publications
- Will Biomarkers Determine What Is Next in Multiple Sclerosis?: Biomarkers in Multiple Sclerosis.
- Primary progressive Multiple sclerosis-why we are failing.
- Dimethyl fumarate in relapsing-remitting Multiple sclerosis: rationale, mechanisms of action, pharmacokinetics, efficacy and safety.
- Clinical management of Multiple sclerosis and neuromyelitis optica with therapeutic monoclonal antibodies: approved therapies and emerging candidates.
- Body fluid biomarkers in Multiple sclerosis: how far we have come and how they could affect the clinic now and in the future.
- The genetics of natalizumab hypersensitivity: One learns to itch where one can scratch.
- A systematic review of the incidence and prevalence of sleep disorders and seizure disorders in Multiple sclerosis.
- A systematic review of the incidence and prevalence of cancer in Multiple sclerosis.
- The incidence and prevalence of comorbid gastrointestinal, musculoskeletal, ocular, pulmonary, and renal disorders in Multiple sclerosis: A systematic review.
- High-Dose Immunosuppressive Therapy and Autologous Hematopoietic Cell Transplantation for Relapsing-Remitting Multiple Sclerosis (HALT-MS): A 3-Year Interim Report.
- Testing effects of glatiramer acetate and fingolimod in an infectious model of CNS immune surveillance.
- Immune surveillance of the central nervous system in Multiple sclerosis - Relevance for therapy and experimental models.
- CD19 as a molecular target in CNS autoimmunity.
- Does Natalizumab Therapy Benefit Patients With Multiple Sclerosis?
- Multiple sclerosis: Natalizumab to fingolimod-the washout whitewash.
- Alemtuzumab: The advantages and challenges of a novel therapy in MS.
- Defining the clinical course of Multiple sclerosis: The 2013 revisions.
- Para-dichlorobenzene toxicity - a review of potential neurotoxic manifestations.
- Does risk stratification decrease the risk of natalizumab-associated PML? Where is the evidence?
- Multiple sclerosis Disease progression and paradichlorobenzene: a tale of mothballs and toilet cleaner.
- Interferon beta use and disability prevention in relapsing-remitting Multiple sclerosis.
- A peptide prime-DNA boost immunization protocol provides significant benefits as a new generation A?42 DNA vaccine for Alzheimer Disease.
- Objective characterization of the relative afferent pupillary defect in MS.
- Rituximab dosing and monitoring strategies in neuromyelitis optica patients: creating strategies for therapeutic success.
- Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy.
- Immunopathogenesis of neuromyelitis optica.
- Symptomatic therapy in Multiple sclerosis.
- Glatiramer acetate attenuates pro-inflammatory T cell responses but does not directly protect neurons from inflammatory cell death.
- Considerations on discontinuing natalizumab for the treatment of Multiple sclerosis.
- Memory B cells from a subset of treatment-naïve relapsing-remitting Multiple sclerosis patients elicit CD4(+) T-cell proliferation and IFN-γ production in response to ...
- Memantine for cognitive impairment in Multiple sclerosis: a randomized placebo-controlled trial.
- Analyses of cerebrospinal fluid in the diagnosis and monitoring of Multiple sclerosis.
- Transcriptional modulation of the immune response by peroxisome proliferator-activated receptor-{alpha} agonists in autoimmune Disease.
- Immunologic mechanisms of Multiple sclerosis.
- The death domain-containing kinase RIP1 regulates p27(Kip1) levels through the PI3K-Akt-forkhead pathway.
- Reactivation of human herpesvirus-6 in natalizumab treated Multiple sclerosis patients.
- Intense immunosuppression in patients with rapidly worsening Multiple sclerosis: treatment guidelines for the clinician.
- Spotlight on statins.
- Autologous HSCT for advanced MS: is the glass half-empty or really half-full?
- W. Ian McDonald, MB, ChB, PhD (1933-2006): the Multiple sclerosis physician-scientist of the 20th century.
- Optical coherence tomography in Multiple sclerosis.
- Statins in the treatment of central nervous system autoimmune Disease.
- Most patients with Multiple sclerosis or a clinically isolated demyelinating syndrome should be treated at the time of diagnosis.
- Characterizing the mechanisms of progression in Multiple sclerosis: evidence and new hypotheses for future directions.
- Single nucleotide polymorphisms in MHC2TA, the gene encoding the MHC class II transactivator (CIITA).
- Requirement for endocytic antigen processing and influence of invariant chain and H-2M deficiencies in CNS autoimmunity.
- Multiple sclerosis flares associated with recombinant granulocyte colony-stimulating factor.
- Migratory behavior of lymphocytes isolated from Multiple sclerosis patients: effects of interferon beta-1b therapy.
- Interferon beta in the treatment of Multiple sclerosis: mechanisms of action.
- Chemokine-enhanced migration of human Peripheral blood mononuclear cells is antagonized by interferon beta-1b through an effect on matrix metalloproteinase-9.
- The value of routine computed tomography of the brain in the pre-operative assessment of patients for carotid endarterectomy.
Schools
Freie Universitaet Berlin Medizinische Fachbereich
University Of Wa School Of Med
Conditions Treated
- Alzheimer's Disease
- Dementia
- Dystonia
- Epilepsy
- View All
Doctors Specialties
- Neurology
Accepted Insurances
Education
-
University of Washington -
Freie University Berlin Faculty of Medicine
Hospital
-
University of Texas Southwestern Medical Center -
Veterans Affairs North Texas Health Care System
Helpful Reviews
Similar Doctors
|
|
Dr. Jeffrey L. Elliott, MD |
|
|
Dr. Mike A. Singer, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David Chen, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael I. Vengrow, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ashby T. Harris, MD |
|
|
Dr. Steven P. Herzog, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kyle B. Womack, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Keith E. Tansey, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John Hart Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Choon H. Cha, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stephen C. Cannon, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Hamid H. Kadiwala, MD
This Doctor is OpenDoctor Recommended.
|